Bone Research (Sep 2023)

Osteomodulin downregulation is associated with osteoarthritis development

  • Jérémie Zappia,
  • Qiao Tong,
  • Renée Van der Cruyssen,
  • Frederique M. F. Cornelis,
  • Cécile Lambert,
  • Tiago Pinto Coelho,
  • Juliane Grisart,
  • Erika Kague,
  • Rik J. Lories,
  • Marc Muller,
  • Dirk Elewaut,
  • Chrissy L. Hammond,
  • Christelle Sanchez,
  • Yves Henrotin

DOI
https://doi.org/10.1038/s41413-023-00286-5
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Abnormal subchondral bone remodeling leading to sclerosis is a main feature of osteoarthritis (OA), and osteomodulin (OMD), a proteoglycan involved in extracellular matrix mineralization, is associated with the sclerotic phenotype. However, the functions of OMD remain poorly understood, specifically in vivo. We used Omd knockout and overexpressing male mice and mutant zebrafish to study its roles in bone and cartilage metabolism and in the development of OA. The expression of Omd is deeply correlated with bone and cartilage microarchitectures affecting the bone volume and the onset of subchondral bone sclerosis and spontaneous cartilage lesions. Mechanistically, OMD binds to RANKL and inhibits osteoclastogenesis, thus controlling the balance of bone remodeling. In conclusion, OMD is a key factor in subchondral bone sclerosis associated with OA. It participates in bone and cartilage homeostasis by acting on the regulation of osteoclastogenesis. Targeting OMD may be a promising new and personalized approach for OA.